Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Eder

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapyK Antman, L Ayash, A Elias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomasL J Ayash, M Hunt, K Antman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancersNancy L Lewis, Lionel D Lewis, Joseph P Eder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1992
Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor responseL J Ayash, J E Wright, O Tretyakov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow supportA D Elias, L J Ayash, J P Eder, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I studyA D Elias, L J Ayash, J P Eder, et al.
The Lancet. Oncology|March 4, 2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planJoanna A Gibson, Karin E Finberg, ILKe Nalbantoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.
Seminars in Oncology|February 1, 1990
High-dose thiotepa alone and in combination regimens with bone marrow supportK Antman, J P Eder, A Elias, et al.
Journal of the National Cancer Institute|October 5, 1988
Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumorsJ P Eder, K Antman, A Elias, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapyK Antman, L Ayash, A Elias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomasL J Ayash, M Hunt, K Antman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancersNancy L Lewis, Lionel D Lewis, Joseph P Eder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1992
Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor responseL J Ayash, J E Wright, O Tretyakov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow supportA D Elias, L J Ayash, J P Eder, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I studyA D Elias, L J Ayash, J P Eder, et al.
The Lancet. Oncology|March 4, 2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planJoanna A Gibson, Karin E Finberg, ILKe Nalbantoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.
Seminars in Oncology|February 1, 1990
High-dose thiotepa alone and in combination regimens with bone marrow supportK Antman, J P Eder, A Elias, et al.
Journal of the National Cancer Institute|October 5, 1988
Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumorsJ P Eder, K Antman, A Elias, et al.
Pageof 12